leadf
logo-loader
viewFirst Majestic Silver Corp.

First Mining Gold closes US$22.5M silver stream deal with First Majestic for Springpole asset

The proceeds will be used to advance the asset through the pre-feasibility stage (PFS) and the environmental assessment processes

First Majestic Silver Corp. -
First Majestic will have the right to buy 50% of the silver produced from Springpole over its life

First Mining Gold Corp (TSE: FF) (OTCQX:FFMGF) has now closed the three-stage US$22.5 million financing deal with shareholder First Majestic Silver Corp (TSE:FR) to advance its flagship Springpole gold project in Ontario - one of the largest undeveloped open pit projects in Canada.

The proceeds will be used to advance the asset through the pre-feasibility stage (PFS) and the environmental assessment processes, the company said in a statement.

READ: First Mining Gold strikes US$22.5M financing deal with First Majestic Silver Corp to advance Springpole gold project

First Majestic will have the right to buy 50% of the silver produced from Springpole over its life. First Majestic has paid upfront US$10 million to First Mining - US$2.5 million in cash and the remaining US$7.5 million in shares.

Upon completion of a positive pre-feasibility study, First Mining will receive US$7.5 million with a further US$5 million payable upon it receiving approval of a federal or provincial environmental assessment for the project.

Springpole currently hosts 4.67 million ounces of gold in the indicated category and 0.23 million ounces gold in inferred. A preliminary economic assessment (PEA) released last year showed an open-pit mine and milling process with the potential to produce an average of 410,000 ounces of gold per year.

Shares ticked up 5.7% in Toronto toC$0.46 each.

---Updates for share price---

Contact the author at [email protected]

Quick facts: First Majestic Silver Corp.

Price: 13.58 CAD

TSX:FR
Market: TSX
Market Cap: $3.01 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals enrolls final patient in Phase 2b/3 human study of...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has enrolled their final patient multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19. Moreau telling Proactive the aggregate...

37 minutes ago

2 min read